The global Developmental and Epileptic Encephalopathies (DEE) Treatment Market is expected to garner a market value of US$ 7 Billion in 2023 and is expected to accumulate a market value of US$ 11.4 Billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for Developmental and Epileptic Encephalopathies (DEE) Treatment registered a CAGR of 3.5% in the historical period 2018 to 2022.
The Developmental and Epileptic Encephalopathies (DEE) Treatment market is a segment of the healthcare industry that deals with the effective management of the condition. Developmental and Epileptic Encephalopathies (DEE) are a group of rare and severe epilepsy syndromes that affect infants and young children. These conditions are characterized by frequent seizures that can cause developmental delays and intellectual disabilities. Currently, there are limited treatment options for DEE, and the prognosis for affected individuals can be poor.
The treatment market for DEE is relatively small due to the rarity of the condition, but there is a growing need for effective therapies to improve the lives of affected individuals. Currently, the most common treatments for DEE include antiepileptic medications and ketogenic diets. However, these treatments are not always effective and can have significant side effects.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 7 Billion |
| Anticipated Forecast Value (2033) | US$ 11.4 Billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Developmental and Epileptic Encephalopathies (DEE) Treatment reflected a value of 3.5% during the historical period, 2018 to 2022. The development of new drugs and therapies is expected to drive market growth. There are several emerging therapies in development for the treatment of DEE, including new antiepileptic medications, gene therapies, and neurostimulation devices. Some of these therapies are in early stages of development, while others are in late-stage clinical trials.
One promising therapy for DEE is the use of cannabidiol (CBD), a non-psychoactive component of cannabis. Several clinical trials have shown that CBD can significantly reduce the frequency of seizures in children with DEE, and the U.S. Food and Drug Administration (FDA) has approved a CBD-based medication for the treatment of two rare forms of childhood epilepsy.
Another emerging therapy for DEE is gene therapy, which involves the delivery of functional genes to replace or repair faulty genes that cause the condition. Several gene therapies are currently in development for DEE, including one that targets a specific genetic mutation that is associated with a severe form of the condition.
Overall, the market for Developmental and Epileptic Encephalopathies (DEE) Treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Increasing incidence of chronic brain injuries to push the market growth
The developmental and epileptic encephalopathies (DEE) treatment market is expected to grow in the coming years due to several factors. One of the key drivers of market growth is the increasing awareness and diagnosis of DEE, which has led to a growing demand for effective therapies. Additionally, the rising prevalence of DEE and the associated high unmet medical needs are also driving the growth of the treatment market.
Another factor driving market growth is the increasing research and development activities in the field of DEE treatment. The development of novel therapies, such as gene therapies and neurostimulation devices, is expected to significantly improve the treatment options for DEE in the coming years. Additionally, the increasing use of cannabidiol (CBD) for the treatment of DEE is expected to contribute to the growth of the market.
Furthermore, the favorable regulatory environment for the development and approval of rare disease therapies is also expected to drive market growth. Regulatory agencies, such as the U.S. FDA, have implemented expedited pathways for the development and approval of rare disease treatments, which could benefit the DEE treatment market.
In conclusion, the DEE treatment market is expected to grow in the coming years due to the increasing awareness and diagnosis of the condition, the development of novel therapies, and the favorable regulatory environment. However, the market still faces several challenges that need to be addressed to ensure the availability and affordability of effective treatments for individuals with DEE.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
DEE is a rare condition, which means that the patient population is small. This can make it challenging for companies to recoup their investment in the development of treatments for DEE.
The development of treatments for rare diseases is typically expensive due to the limited patient population, which can increase the cost per patient. Additionally, regulatory requirements for rare disease treatments can be more stringent, which can also increase the cost of development.
Increasing awareness and diagnosis of DEE Shaping Landscape for Developmental and Epileptic Encephalopathies (DEE) Treatment in South & East Asia
The Developmental and Epileptic Encephalopathies (DEE) Treatment Market in the South & East Asia region is currently in its early stages of development. However, the market is expected to grow significantly in the coming years due to several factors.
One of the key drivers of market growth in the region is the increasing awareness and diagnosis of DEE, which has led to a growing demand for effective therapies. Additionally, the rising prevalence of DEE and the associated high unmet medical needs are also driving the growth of the treatment market.
Another factor driving market growth is the increasing research and development activities in the field of DEE treatment. The development of novel therapies, such as gene therapies and neurostimulation devices, is expected to significantly improve the treatment options for DEE in the coming years.
Furthermore, the favorable regulatory environment for the development and approval of rare disease therapies is also expected to drive market growth in the region. Regulatory agencies in the region, such as the National Medical Products Administration (NMPA) in China, have implemented expedited pathways for the development and approval of rare disease treatments, which could benefit the DEE treatment market.
Increasing Focus on Technological advancements Shaping Landscape for Developmental and Epileptic Encephalopathies (DEE) Treatment in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. The prevalence of DEE is increasing in North America, which is driving the demand for effective treatments for the condition. Regulatory agencies in North America, such as the U.S. FDA, have implemented expedited pathways for the development and approval of rare disease treatments, which could benefit the DEE treatment market.
There is a growing focus on the development of novel therapies for DEE in North America, including gene therapies, neurostimulation devices, and cannabinoid-based treatments.
In conclusion, the market for DEE treatment in North America is being boosted by several factors, including increasing prevalence, favorable regulatory environment, increasing research and development activities, rising awareness and diagnosis, growing healthcare infrastructure, and availability of funding. These factors are expected to contribute to the growth of the DEE treatment market in North America in the coming years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Oral segment to hold a significant share and push market growth
The oral segment is likely to account for a significant share of the market. This is primarily because oral medications are the mFost commonly prescribed and convenient route of administration for patients with DEE. Oral medications can be taken at home and do not require healthcare provider administration, which can improve patient compliance and adherence to treatment.
In addition, several oral medications, such as antiepileptic drugs, are already approved for the treatment of DEE and have a well-established safety and efficacy profile. This makes it easier for physicians to prescribe these medications for the treatment of DEE, which could drive market growth.
Furthermore, the development of new oral medications, such as cannabidiol-based treatments, could also drive market growth in the oral segment. These medications have shown promise in the treatment of DEE and could expand the treatment options available to patients.
Hospital Pharmacies to take the lead and drive market growth
Hospital pharmacies are likely to account for a significant share of the market. This is primarily because DEE is a rare and complex condition that requires specialized care and expertise. Patients with DEE often require hospitalization for diagnosis and treatment, which can increase the likelihood of hospital pharmacies being the primary distribution channel for DEE treatments.
In addition, hospital pharmacies often have direct access to healthcare p &NBSroviders and can facilitate the timely provision of medications to patients. This can be particularly important in the case of DEE, where prompt treatment can be critical for preventing long-term complications and improving outcomes.
Key players in the market include companies such as Jazz Pharmaceuticals, Biocodex, Zogenix, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Eisai Pharmaceuticals, Lundbeck, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Xenon Pharmaceuticals, Praxis Precision Medicines, Longboard Pharmaceuticals, Stoke Therapeutics, Takeda Therapeutics, Epygenix Therapeutics, SK Life Science, BioPharm Solutions, along with healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 7 Billion |
| Market Value in 2033 | US$ 11.4 Billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled | Bayer, Attgeno AB, Cereno Scientific AB, Bial - Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmed, Altavant Sciences, Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., |
| Customization | Available Upon Request |
The market will register a 6% CAGR through 2033.
From 2018 to 2022, the market registered a CAGR of 3.5%.
The global market will reach US$ 11.4 billion by 2033.
South & East Asia is projected to emerge as a lucrative market.
North America is likely to generate 40% revenue by 2033.
1. Executive Summary | Developmental and Epileptic Encephalopathies (DEE) Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Lamictal 5.3.2. Felbatol 5.3.3. Clonazepam 5.3.4. Onfi 5.3.5. Cannabidiol 5.3.6. Rufinamide 5.3.7. Vigabatrin 5.3.8. Stiripentol 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Topical 6.3.2. Oral 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033 7.3.1. Hospital Pharmacy 7.3.2. Online Pharmacy 7.3.3. Retail Pharmacy 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Class 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Class 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Class 14.2.3. By Route of Administration 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Class 15.2.3. By Route of Administration 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Class 16.1.2.2. By Route of Administration 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Class 16.2.2.2. By Route of Administration 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Class 16.3.2.2. By Route of Administration 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Class 16.4.2.2. By Route of Administration 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Class 16.5.2.2. By Route of Administration 16.5.2.3. By Distribution Channel 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Class 16.6.2.2. By Route of Administration 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Class 16.7.2.2. By Route of Administration 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Class 16.8.2.2. By Route of Administration 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Class 16.9.2.2. By Route of Administration 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Class 16.10.2.2. By Route of Administration 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Class 16.11.2.2. By Route of Administration 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Class 16.12.2.2. By Route of Administration 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Class 16.13.2.2. By Route of Administration 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Class 16.14.2.2. By Route of Administration 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Class 16.15.2.2. By Route of Administration 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Class 16.16.2.2. By Route of Administration 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Class 16.17.2.2. By Route of Administration 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Class 16.18.2.2. By Route of Administration 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Class 16.19.2.2. By Route of Administration 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Class 16.20.2.2. By Route of Administration 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Class 16.21.2.2. By Route of Administration 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Jazz Pharmaceuticals 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Biocodex 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Zogenix 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Marinus Pharmaceuticals 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Novartis 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Aquestive Therapeutics 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Supernus Pharmaceuticals 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Lundbeck 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Eisai Pharmaceuticals 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. GlaxoSmithKline 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. Meda Pharmaceuticals 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.12. Roche 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 18.1.13. Xenon Pharmaceuticals 18.1.13.1. Overview 18.1.13.2. Product Portfolio 18.1.13.3. Profitability by Market Segments 18.1.13.4. Sales Footprint 18.1.13.5. Strategy Overview 18.1.13.5.1. Marketing Strategy 18.1.14. Praxis Precision Medicines 18.1.14.1. Overview 18.1.14.2. Product Portfolio 18.1.14.3. Profitability by Market Segments 18.1.14.4. Sales Footprint 18.1.14.5. Strategy Overview 18.1.14.5.1. Marketing Strategy 18.1.15. Longboard Pharmaceuticals 18.1.15.1. Overview 18.1.15.2. Product Portfolio 18.1.15.3. Profitability by Market Segments 18.1.15.4. Sales Footprint 18.1.15.5. Strategy Overview 18.1.15.5.1. Marketing Strategy 18.1.16. Stoke Therapeutics 18.1.16.1. Overview 18.1.16.2. Product Portfolio 18.1.16.3. Profitability by Market Segments 18.1.16.4. Sales Footprint 18.1.16.5. Strategy Overview 18.1.16.5.1. Marketing Strategy 18.1.17. Takeda Therapeutics 18.1.17.1. Overview 18.1.17.2. Product Portfolio 18.1.17.3. Profitability by Market Segments 18.1.17.4. Sales Footprint 18.1.17.5. Strategy Overview 18.1.17.5.1. Marketing Strategy 18.1.18. Epygenix Therapeutics 18.1.18.1. Overview 18.1.18.2. Product Portfolio 18.1.18.3. Profitability by Market Segments 18.1.18.4. Sales Footprint 18.1.18.5. Strategy Overview 18.1.18.5.1. Marketing Strategy 18.1.19. SK Life Science 18.1.19.1. Overview 18.1.19.2. Product Portfolio 18.1.19.3. Profitability by Market Segments 18.1.19.4. Sales Footprint 18.1.19.5. Strategy Overview 18.1.19.5.1. Marketing Strategy 18.1.20. BioPharm Solutions 18.1.20.1. Overview 18.1.20.2. Product Portfolio 18.1.20.3. Profitability by Market Segments 18.1.20.4. Sales Footprint 18.1.20.5. Strategy Overview 18.1.20.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Healthcare
February 2023
REP-GB-16711
298 pages
Explore Healthcare Insights
View Reports
Developmental and Epileptic Encephalopathies (DEE) Treatment Market
